Inflammatory bowel diseases (IBD) manifest not only in the gastrointestinal (GI) tract, but also affect joints, skin, eyes, liver, lung, and pancreas. Up to half of patients with IBD have extraintestinal manifestations (EIMs) of IBD. Therapies for intestinal inflammation are not sufficient to treat EIMs such as anterior uveitis, ankylosing spondylitis, and primary sclerosing cholangitis (PSC), which usually occur independent of disease flares. In the October issue of Gastroenterology, Gerhard Rogler et al review the epidemiology, pathophysiology, clinical presentation, and treatment of EIMs in patients with IBD.
Trending
- 3 gastroenterology physicians face lawsuits in 1 week (Becker’s GI & Endoscopy)
- Centralized Colorectal Cancer Screening Outreach in Federally Qualified Health Centers (JAMA Network)
- Gut Check: New Study Challenges Gastroparesis Diagnostics (GI & Endoscopy News)
- Capitalizing On The GI M&A Market, With Sap Sinha (Podcast) (The Corner Series)
- As GLP-1 Use Surges, Clinicians Weigh Benefits and Risks (Medscape)
- New HHS leader could overhaul Medicare physician reimbursement: reports (Medical Economics)
- UnitedHealth pays its own physician groups considerably more than others, driving up consumer costs and its profits (STAT)
- Innovating Personalized Care: The Future of Gastroenterology (ASGE)